Advisor Group’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Advisor Group’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-57	Closed	–	–	5558
2019 Q3	$0	Sell	57 -1	-2%	-$7	﹤0.01%	5530
2019 Q2	$1K	Hold	58	–	–	﹤0.01%	5185
2019 Q1	$2K	Hold	58	–	–	﹤0.01%	5001
2018 Q4	$1K	Sell	58 -267	-82%	-$10.4K	﹤0.01%	5052
2018 Q3	$18K	Buy	325 +200	+160%	+$12.8K	﹤0.01%	3966
2018 Q2	$9K	Hold	125	–	–	﹤0.01%	4151
2018 Q1	$8K	Hold	125	–	–	﹤0.01%	4231
2017 Q4	$16K	Hold	125	–	–	﹤0.01%	3839
2017 Q3	$17K	Hold	125	–	–	﹤0.01%	3669
2017 Q2	$18K	Hold	125	–	–	﹤0.01%	3576
2017 Q1	$23K	Buy	+125	New	+$14K	﹤0.01%	3296
2016 Q4	–	Sell	-67	Closed	-$5K	–	4708
2016 Q3	$5K	Hold	67	–	–	﹤0.01%	3931
2016 Q2	$5K	Buy	+67	New	+$6.14K	﹤0.01%	3813

Other funds holding TTPH

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Advisor Group's TTPH Position: Q4 2019 in Review

Advisor Group sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q4 2019, closing a stake of 57 shares.

Advisor Group first reported a position in TTPH in Q2 2016 and held it in 13 quarters. The position peaked at $23K in Q1 2017. 23 funds tracked by Wall St. Rank hold TTPH as of Q4 2019.

Advisor Group reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Advisor Group sold 57 Tetraphase Pharmaceuticals, Inc. shares in Q4 2019.
Advisor Group first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2016 and held it in 13 quarters.
Advisor Group's Tetraphase Pharmaceuticals, Inc. position peaked at $23K in Q1 2017.
23 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.